Fintepla (Fenfluramine HCl) Patent Expiration, LOE Window & CMS Spending
Fintepla (Fenfluramine HCl) by Ucb: FDA Orange Book core substance LOE 2037-06-20 (last listed 2038-12-29), 0 AB generics, $230.7M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ucb |
| FDA Application & Pathway | N212102 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2037-06-20 |
| Last Listed Patent or Exclusivity Date | 2038-12-29 |
| Orange Book Patents (*PED Extensions) | 27 patents (14 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $230.7M |
| 2024 Medicare Part D Spend | $40.9M |
| 2024 Medicaid Spend | $189.8M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 20.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.